268 related articles for article (PubMed ID: 27374174)
1. MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer.
Chen Y; Du M; Wang J; Xing P; Zhang Y; Li F; Lu X
Oncotarget; 2016 Jul; 7(30):48432-48442. PubMed ID: 27374174
[TBL] [Abstract][Full Text] [Related]
2. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X
World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709
[TBL] [Abstract][Full Text] [Related]
3. CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection.
Ji X; Shen Z; Zhao B; Yuan X; Zhu X
Medicine (Baltimore); 2018 Mar; 97(10):e0101. PubMed ID: 29517684
[TBL] [Abstract][Full Text] [Related]
4. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive significance of plasma hepatocyte growth factor and carcinoembryonic antigen in non-small lung cancer after surgery.
Fang MY; Wang SY; Zheng YB; Gong LY; Bao WL; Gu DL; Mao WM
Eur Rev Med Pharmacol Sci; 2014; 18(3):398-403. PubMed ID: 24563441
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion.
Hao J; Zeltz C; Pintilie M; Li Q; Sakashita S; Wang T; Cabanero M; Martins-Filho SN; Wang DY; Pasko E; Venkat K; Joseph J; Raghavan V; Zhu CQ; Wang YH; Moghal N; Tsao MS; Navab R
Neoplasia; 2019 May; 21(5):482-493. PubMed ID: 30978569
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-β1 and α-smooth muscle actin in stromal fibroblasts are associated with a poor prognosis in patients with clinical stage I-IIIA nonsmall cell lung cancer after curative resection.
Chen Y; Zou L; Zhang Y; Chen Y; Xing P; Yang W; Li F; Ji X; Liu F; Lu X
Tumour Biol; 2014 Jul; 35(7):6707-13. PubMed ID: 24711139
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer.
Tsao MS; Yang Y; Marcus A; Liu N; Mou L
Hum Pathol; 2001 Jan; 32(1):57-65. PubMed ID: 11172296
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC.
Schulze AB; Schmidt LH; Heitkötter B; Huss S; Mohr M; Marra A; Hillejan L; Görlich D; Barth PJ; Rehkämper J; Evers G
Thorac Cancer; 2020 Jan; 11(1):120-129. PubMed ID: 31760702
[TBL] [Abstract][Full Text] [Related]
11. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
13. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1.
Mao M; Wu Z; Chen J
Biochem Biophys Res Commun; 2016 Sep; 478(2):649-55. PubMed ID: 27495872
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
Liu L; Qu W; Zhong Z
Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
[TBL] [Abstract][Full Text] [Related]
16. Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer.
Alcaraz J; Carrasco JL; Millares L; Luis IC; Fernández-Porras FJ; Martínez-Romero A; Diaz-Valdivia N; De Cos JS; Rami-Porta R; Seijo L; Ramírez J; Pajares MJ; Reguart N; Barreiro E; Monsó E
Lung Cancer; 2019 Sep; 135():151-160. PubMed ID: 31446988
[TBL] [Abstract][Full Text] [Related]
17. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
Liu J; Ping W; Zu Y; Sun W
Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
[TBL] [Abstract][Full Text] [Related]
18. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Han JY; Kim JY; Lee SH; Yoo NJ; Choi BG
Lung Cancer; 2011 Nov; 74(2):293-9. PubMed ID: 21440951
[TBL] [Abstract][Full Text] [Related]
19. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
[TBL] [Abstract][Full Text] [Related]
20. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
